OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-06-30-accounts

Company Number: 1645201 Charity Number: 285174 OSCR Number: SC041209

The British Thoracic Society Annual Report and financial statements for the year ended 30 June 2022

TABLE OF CONTENTS
Foreword from the Chair of the Board of Trustees 1
Trustees’ Annual Report:-
Our strategy and purpose 2
Audiences, beneficiaries and public benefit 4
Achievements and performance 5
Outcomes and impact measures 11
Financial review 13
Structure, governance and management 15
Statement of responsibilities of Trustees 18
Reference and administrative details 19
Independent auditor’s report 21
Statement of financial activities (incorporating an income and expenditure account) 24
Balance sheet 25
Statement of cash flows 26
Notes to the financial statements 27
Appendix A: BTS members actively involved in Society activities during the year 41
Appendix B: external funding/support received in respect of annual conferences and 46
courses

The Trustees of the British Thoracic Society (BTS) present our report and the audited financial statements for the year ended 30 June 2022. The reference and administrative information set out on page 19 forms part of this report.

The Society’s work for the year to 30 June 2022 has been dominated by the COVID-19 pandemic with a focus on restoring activity in a number of our key work programmes. BTS members continued to be at the forefront - treating patients with acute COVID infections throughout the surge in cases over the winter period, as well as restoring and re-configuring services as infection levels dropped. The Board has ensured that the Society’s response to these extraordinarily challenging times has remained rigorous and timely, while upholding the BTS reputation for authenticity and authority. The Society has published an Impact Report for 2021/22 highlighting key activities and achievements.

The financial statements comply with the Charities Act 2011; the Companies Act 2006; the Memorandum and Articles of Association; and the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

CHAIR’S FOREWORD

I am delighted to introduce the 2022 BTS Annual Report. Alongside the Impact Report 2021-22 this showcases the breadth and reach of the Society’s work in a multitude of different areas. The outputs are the work of hundreds of different BTS members plus the talented and dedicated staff team; I would like to thank every person for their contribution and hope they are proud of the work of their Society.

It was a great honour to take over as chair at the end of 2021. Jon Bennett set a very high standard to follow and I only hope I can deliver as much as he did for respiratory professionals, patients and their carers. The latter part of Jon’s tenure was dominated by COVID-19 and, as a fellow Officer during part of that time, I retain nothing but admiration for his leadership of the Society and specialty. Current challenges may be less acute but will ask no less of respiratory professionals.

The profile of respiratory medicine rose significantly during this period, and the pandemic also heralded many changes in respiratory practice. There will be some changes we retain and others we don’t but undoubtedly we now connect better with our partners and plan to build on both new and reignited relationships. During this time, BTS has changed too, becoming more agile in producing clinical guidance and incorporating new ways of working and delivering education and support. The election of Ms Rachael Moses, the Society’s first non-doctor President, is one of seminal importance. Rachael has shown us what we were missing and both her knowledge and skill, and passion and enthusiasm has been an inspiration for me and so many others. This is only the start, the foundation on which to build the multi-professional leadership of the BTS and respiratory medicine.

To deliver ‘better lung health for all’ we need more respiratory professionals and this remains a core focus. BTS continues to work closely with our many partners, reinforcing the call for an urgent increase in the respiratory workforce, as set out in our recent report ‘A respiratory workforce for the future.’ BTS is also involved in initiatives designed to prevent wider harm to both the public and the planet. Treatment of tobacco dependency remains a priority and we are managing a UK-wide Tobacco Dependency Project via our Respiratory Futures platform. We are also working to promote clean air and a reduction in emissions in partnership with UKHACC, and this led to our new Position Statement on Air Quality. As members and as respiratory professionals, we can all play a role in thinking about global issues including sustainability in healthcare and its impact on the environment.

The past year has also highlighted new and developing challenges. The ‘cost of living crisis’ is already having a huge impact on respiratory patients and their ability to run vital equipment and afford essential medicines. Restart and resumption of services has further revealed unmet need and shown the consequences of delays in care. COVID-19 has again shown the impact of health and social inequality on lung health. As a Society, and community, we will continue to highlight these issues and contribute to addressing these challenges.

Finally, as Chair I believe it is vital that our work and priorities are directed by listening to our members. BTS has recently conducted its member survey and we will use the sentiments and views expressed to determine our priorities and future workplan. Over the coming months, the Board, our Council and the staff team will be working on a new strategy, ensuring the Society stays relevant and can reach even more people over the next three years. It is a journey I am excited to begin.

Dr Paul Walker

Chair of the Board of Trustees

1

OUR STRATEGY AND PURPOSE

The Board of Trustees (“the Board”) has continued to lead the Society through another year in which the pandemic has continued to occupy respiratory professionals across the country. For 2021/22, the Society has continued to focus on its stated strategic priorities as set out below.

Our Vision

Better lung health for all

Our Mission

Our Objectives

The following priority areas for the year:

2

Several over-arching themes continued to influence the thinking of Trustees.

Annual Review

The Board reviews progress against objectives every year and presents the outcome in this Report. This review helps the Trustees to make sure that the Society’s aims, objectives and activities remain focussed on its stated purposes. The Board plans to publish an updated strategy for the Society for 2023 – 2025 later in 2022.

The Society’s strategy was summarised within the following diagrammatic plan:

3

AUDIENCES, BENEFICIARIES AND PUBLIC BENEFIT

The principle underpinning our strategic plan remains that the vast majority of our information, publications, clinical standards related tools and activities are widely and freely available via the BTS website . These are of benefit to health care professionals (not just BTS members) who will use our work to improve practice locally, which will in turn benefit patients. Information contained on the BTS and Respiratory Futures websites is also freely accessible to members of the public.

COVID-19

The Society continued to disseminate and update the range of COVID-19 guidance documents produced during the first year of the pandemic, and introduced new documents to support a restoration and resumption of services. The Society’s Head Office remained closed to visitors until early 2022, with staff returning to work flexibly, now working both in the office and at home.

Conferences and events

The 2021 Winter Meeting was held online in November 2021 attracting 1627 delegates. Delegates benefited from access to the entire programme which was available on demand for 90 days after the event. The Summer Meeting returned to an onsite venue in June 2022, providing a welcome opportunity for face to face networking. The BTS programme of short courses continued to attract high numbers of delegates to those courses offered as online only, with a small number of courses supporting practical skills returning to an in person format. This combination of onsite and online will be an enduring feature of our programme of continuing professional development going forward.

Workforce

Workforce remains a key priority for the Society. The Society published a landmark report in May 2022 “A Respiratory workforce for the future” illustrating the vital importance of the multi-professional respiratory team, highlighting the additional staffing required across all respiratory professions and featuring calls for a number of changes in resourcing, training and commissioning that must be put in place to ensure the NHS has a sustainable respiratory workforce today and in the future. This important report has been shared widely with stakeholders and those in leadership positions within the NHS across the four nations. BTS continued to respond to calls for evidence to highlight the importance of the respiratory workforce and has collaborated with other organisations to ensure the collective respiratory voice is heard.

Air Quality

In June, 2022 BTS published its first position statement on air quality and lung health. The Board convened a small task and finish group to provide the necessary specialist input to this document. The Statement highlights issues surrounding poor indoor, outdoor and ambient air quality, and focusses on where the Society will act, and the role of health professionals and Government.

Respiratory Futures

Our Respiratory Futures programme provides a focus for our work supporting integrated care, and the linked website promotes cross-boundary working and facilitates the sharing of best practice. Respiratory Futures enables us to engage with a wider audience, which includes commissioners and managers of healthcare services and just over 1800 people receive a regular mailing from Respiratory Futures. Development work on the website continues to establish this platform as a key resource for sharing relevant resources most notably in support of our tobacco dependence workstream.

Inclusion, Diversity, Equality

BTS is a membership organisation which exists to improve the care and health outcomes of people who have lung disease. We can only achieve our aim by harnessing the experience, knowledge, skills and contributions of our members, supported by a small staff team, and involving people with lung diseases in the development of our advice about service development and clinical management. BTS published its first Policy statement on Inclusion, Diversity and Equality (IDE) in June 2021 and has continued to work throughout the year to take steps to deliver the actions stated in the document.

4

ACHIEVEMENTS & PERFORMANCE

We describe our three main areas of activity in the Statement of Financial Activities (the SOFA) as follows.

Standards, workforce and education

These activities are undertaken under the direction of the Society’s Standards of Care Committee; the Quality Improvement Committee; the Education and Training Committee; and the Workforce and Service Development Committee, together with the input of the Society’s Specialist Advisory Groups (SAGs), the Specialty Trainees Advisory Group (STAG) and the Nurse Advisory Group.

Research and innovation

The Society achieves objectives in this area by:

Profile

We are committed to working to promote and advance knowledge and awareness of lung health to the public, to healthcare professionals and to policy makers and government bodies. This is done pro-actively and reactively in partnership with other professional societies and lung charities, and via internal and external communications. Our continued membership of the Taskforce for Lung Health is one way of achieving this, as is our membership of the UK Health Alliance on Climate Change. We continue to develop our Respiratory Futures project to reflect the needs of the respiratory health care community and this will benefit from the strengthened communications capacity within BTS Head Office.

STANDARDS, WORKFORCE AND EDUCATION

STANDARDS

We published a number of new clinical standards and quality improvement related documents. Work has continued in a number of other areas which had been halted temporarily by the pandemic, and new activities have been commissioned. Table 1 demonstrates how much the Society relies on our members’ participation, and the debt that the Board owes to all concerned.

5

TABLE 1: STANDARDS AND QUALITY IMPROVEMENT DOCUMENTS

----- Start of picture text -----
PUBLICATION STATUS
Guidelines
BTS Pleural Disease Guideline Due for publication 2022
BTS Guideline on Paediatric Sleep Disorders Due for publication 2022
BTS/SIGN/NICE Guideline for The Diagnosis and Management of Chronic In progress
Asthma
BTS Guideline on Pulmonary Nodules In progress
Quality Standards
We intend that all Guidelines are complemented by a Quality Standards document.
Quality Standards for Bronchiectasis in adults - update Due for publication 2022
Clinical Statements
A “snapshot in time” of knowledge and best practice in a clinical area with clinical practice points.
BTS Clinical Statement on Air Travel for Patients with Lung Disease Published March 2022
BTS Clinical Statement on Occupational Asthma Published March 2022
BTS Clinical Statement on the Diagnosis and Treatment of Ocular Published April 2022
Tuberculosis
BTS Clinical Statement on the Assessment and Management of Respiratory Published April 2022
Problems in Athletes
BTS Clinical Statements on Aspiration Pneumonia and Pneumonia in adults Due for publication 2022
and children with Learning Disabilities
BTS Clinical Statement on Pleural Procedures Due for publication 2022
BTS Clinical Statement on Cough in adults Due for publication 2023
BTS Clinical Statement on Medical Management of tobacco addiction for Due for publication 2023
hospital clinicians
BTS Clinical Statement on Pulmonary Rehabilitation Due for publication 2023
BTS Clinical Statement on the Diagnosis and Management of Aspergillus- Due for publication 2023
related chronic pulmonary disease
Audits
Report for 2021 National Audit of hospital based tobacco dependence
Published June 2022
treatment services
Report for 2021 National pleural services organisational Audit Due for publication 2022
Report for 2021 National Audit of Outpatient Management of Pulmonary
Due for publication 2022
Embolism
Report of the 2021/22 pilot Audit of respiratory support Due for publication 2022
Quality Improvement
Materials to help services put in place a programme of improvement for the management of patients and
their conditions following BTS national audits.
BTS webinar on the use of the NHS Steroid alert card July 2021
BTS risk stratification guidance in relation to field safety notices for July 2021
selected ventilator, CPAP and BiPAP devices.
BTS Lung Disease Registry Programme
The Registry, established in 2013, aims to provide an easily accessed system for prospective data
collection in a large number of patients so that the public health and epidemiological status of conditions
in the UK can be established. The Registry serves as an important resource for clinical and basic research.
The BTS ILD Annual Report for 2021 provided a report on data collected
Published November 2021
from 75 hospitals across the UK.
Multi-drug Resistant Tuberculosis Clinical Advice Service
The second BTS Annual report for the MDR-TB Clinical Advice Service
2021 provided a report on data held on cases considered by the Clinical Published November 2021
Advice Service .
----- End of picture text -----

6

BTS, SIGN and NICE have continued to work together to develop the framework for the production of a new Joint Guideline on the diagnosis and management of chronic asthma . Work on the guideline began in early 2022 and the draft guideline is expected to be available for consultation in mid 2023. The guideline will form part of an agreed range of materials and resources which will aim to cover the whole asthma pathway.

The BTS Lung Disease Registry continued to attract new participants, and work has taken place to ensure that the Registry can provide data to support the forthcoming NHSEI Quality Dashboard for Interstitial Lung Disease.

The new BTS Tobacco Dependency Project was formally commissioned by NHSEI in March 2021, and the Project Manager, Melanie Perry, joined BTS in June 2021. The 3 year project aims to provide a sustainable framework of resources for improving tobacco dependence treatment by supporting clinicians working in NHS services. This project supports clinicians working to build sustainable tobacco dependence treatment services that meet the goals of the NHSE Long Term Plan. Extensive resources have been provided on the Respiratory Futures website and a series of eight open access webinars with over 400 attendees has enabled teams to share learning and best practice.

Patient safety is a significant driver for improvements in respiratory care and this important area will be a focus for the future work of the Quality Improvement Committee. BTS continues to maintain good working links with the NHSEI patient safety team and is regularly contacted to provide advice on patient safety issues. BTS has also assisted in inquiries led by the Healthcare Safety Investigation Branch over the past year.

WORKFORCE

May 2022 saw the landmark publication of A Respiratory Workforce for the Future , a BTS document that celebrates the impact respiratory professionals make across the NHS while highlighting the requirements for expansion across the full multi-professional team.

Workforce and training data collection and reporting continued during the year, and we have continued to work closely with the Respiratory Specialty Advisory Committee (SAC)/Joint Royal College Physicians Training Board (JRCPTB), the Royal Colleges of Physicians, and Regional Training Programme Directors. The range of case studies from respiratory health care professionals continues to be developed including new information provided by Physician Associate, Advanced Clinical Practitioner and Speech and Language Therapy colleagues working in respiratory teams.

7

Chair, Officers and members of the Board to make the case for improved planning arrangements to address Winter Pressures both nationally and locally, and to continue to call for increased numbers of staff across the respiratory team.

The Society provided representation on the Joint Royal Colleges Postgraduate Training Board (JRCPTB) Respiratory Specialty Advisory Committee (SAC). This is currently concerned with the introduction of the new Internal Medicine Curriculum and the updated respiratory specialty curriculum, as well as addressing the issues for those in training presented by the COVID-19 pandemic.

The Workforce and Service Development Committee continued to oversee the Society’s data collection activities in relation to consultant and trainee posts, as well as raising the profile of the full respiratory team. The Committee produced a survey of our trainee members which collected data in order to better understand career intentions and future work patterns. The survey report is available on the BTS website and a commentary paper authored by BTS trainee representatives was published in BMJ Open Respiratory Research .

In 2020 the British Thoracic Society and the Primary Care Respiratory Society agreed to work together in a formal collaboration to support the development of fully integrated respiratory services for patients. The COVID pandemic highlighted how a disjointed and fragmented approach to care has worsened outcomes for patients, heightened health inequalities and the challenge now is to drive forward transformative change towards more effective integrated care. BTS and PCRS continue to meet regularly at an executive level and the joint working group has also continued. Both organisations remain committed to enhanced collaboration and discussions have started to understand what joint activities will serve most benefit for those working across primary and secondary care.

EDUCATION

The Summer Meeting was held as a face to face event in June 2022, attracting nearly 600 delegates. Held at a new venue in Manchester, feedback from the Meeting has been very encouraging with many delegates relishing the opportunity to meet colleagues again.

Our Short Course programme has been offered both online and onsite for the past year and in total has provided 735 places on 10 courses (Table 2), with three of these courses returning to a face to face format.

The Society aims to build on the BTS Training Standards for Thoracic Ultrasound document which was published in May 2020. Work is in progress to develop a new online educational resource to support the theory of thoracic ultrasound . This will support the educational requirements for respiratory physicians, respiratory specialty trainees, respiratory (pleural) specialist nurses and physician associates.

TABLE 2: SHORT COURSE PROGRAMME 2021/2022

----- Start of picture text -----
Short courses July 2021-June 2022 Delegates
Bronchoscopy/Thoracoscopy July 2021 47
Pulmonary Vascular Disease July 2021 56
Oxford Radiology Course September 2021 80
Advanced Pulmonary Rehabilitation November 2021 86
Fundamentals of Pulmonary Rehabilitation February 2022 109
Acute Non Invasive Ventilation (NIV)/Home Mechanical Ventilation (HMV) March 2022 105
Bronchoscopy/Thoracoscopy May 2022 32
Respiratory Physiology May 2022 38
Preparing for the Respiratory SCE June 2022 144
Acute NIV/HMV practical course June 2022 38
Total 735
----- End of picture text -----

8

RESEARCH AND INNOVATION

The Society publishes the journal Thorax in partnership with the British Medical Journal (BMJ). Its Impact Factor (IF) at the end of June 2022 was 9.102.

PROFILE

9

10

OUTCOMES AND IMPACT MEASURES

Quantitative and qualitative measures are obtained and reviewed regularly. Data about visits to the Society’s website and our presence via social media are monitored by the Senior Management Team as a measure of potential impact. Over the course of the past year, greater efforts have been made to represent the respiratory voice via press and other media channels.

BTS marked the 40[th] anniversary of its incorporation in June 2022 at the Summer Meeting in June 2022 and via information on milestones and achievements on the BTS website: - BTS at 40 | British Thoracic Society | Better lung health for all (brit thoracic.org.uk)

Standards

Education

Research

Raising the profile of Respiratory

Key achievements can also be found in the BTS Impact Report for 2021/22: Governance Documents and Policies | British Thoracic Society | Better lung health for all (brit-thoracic.org.uk).

THE BTS HEAD OFFICE TEAM

The Society’s Senior Management Team, comprising Sally Welham, Chief Executive, Louise Preston, Head of Strategic Programmes, Miguel Souto, Head of Clinical Programmes and Kathryn Wilson, Head of Operations was joined by a new colleague in June 2022, Rosie O’Carroll as Head of Strategic Communications.

11

BTS would like to acknowledge and thank all the many respiratory healthcare professionals for their outstanding hard work, flexibility, resilience and compassion which has continued throughout the pandemic. The Society is proud to represent the respiratory community - we applaud all you have done and continue to do for your patients and for the health service.

12

FINANCIAL REVIEW

Core costs

Previous Annual Reports have explained that Trustees had budgeted for a deficit in the last three years, 2019/20, 2020/21 and 2021/22 as a result of considered decisions taken since 2016 to support efforts to raise the respiratory profile. This included the appointment of a number of new members of staff and to ensure that the correct staffing structure was in place to support the long planned retirement of the Chief Executive and the smooth transition to the new Senior Management Team. Trustees still have no doubt that the Society remains a going concern.

We are fortunate to have robust income streams that support our core work. These are membership subscriptions, at £666,540 compared to £658,019 in 2021. At the end of June 2022, we had 4,254 members (4,109 in June 2021, 3,778 in June 2020 and 3,624 in June 2019). The partner’s share of the profit from the journal Thorax and BMJ Open Respiratory Research is the other core income stream. Income from the journals decreased to £565,044 in 2022 compared to £659,894 in 2021 and £646,788 in 2020. This is the expected continuation of an overall downward trend in journal income which the Management Committee for the journals will continue to monitor closely.

Investment Policy and Performance

Management of the BTS investment portfolio is undertaken by Evelyn Partners (formerly Tilney Asset Management). The Society’s Investment Policy is reviewed annually by the Board each December and currently sets out a “Growth Strategy”, which is defined as follows:

“…. appropriate for an investor with a five-year time horizon, who is comfortable with significant volatility of returns and having up to 80% of their portfolio in equities, and who is able to tolerate a loss of up to 20% of the value of the portfolio in any one year”.

Quarterly reports are received from the Investment Managers and bi-annual meetings are held between the investment managers and the Honorary Treasurer and Chief Executive to review progress and assess the approach to management of the funds. The Honorary Treasurer speaks to the Society’s dedicated Investment Manager before each meeting of the Board of Trustees in order to report on progress.

13

The Investment Policy . The instruction not to invest in the tobacco industry or tobacco-related products remains strictly in place. The Investment Policy was amended in 2016 to include the requirement that investments are not made in industries involved in the extraction of fossil fuels or in industries that make weapons. In 2017 Trustees agreed to draw a proportion of the annual investment gain as income to support the Society’s activities.

Reserves

Total funds at 30 June 2022 were £6,779,598 (£6,787,974 in 2021 and £6,354,111 in 2020) comprising restricted funds of £29,342(£112,188 in 2021) and unrestricted funds of £6,750,256 (£6,675,786 in 2021). The Society holds reserves for two purposes. The first is to generate income for its operational needs (the investment reserve). This is held as a designated fund and stands at £4,386,2659 (compared to £4,460,163 in 2021 and £4,074,385 in 2020). The second purpose is to ensure that the Society can meet its operational needs and working capital requirements (the free reserve). The free reserve is represented by the general fund. This stands now at £741,607 (it was £570,346 in 2021 and £449,488 in 2020. At the June 2017 meeting of the Board, it was agreed that the reserve policy should be amended, and maintained in future at a level equivalent to three months’ running costs and contingencies (a minimum of £300,000).

Funds

Interest & Investment income earned has been attributed to individual funds in the ratio of the fund balance to total funds.

14

STRUCTURE, GOVERNANCE AND MANAGEMENT

The British Thoracic Society (“the Society”/ “BTS”) is a charitable company limited by guarantee which has no share capital. It was incorporated on 21 June 1982 and registered as a charity on 21 June 1982. The Office of the Scottish Charity Regulator (OSCR) approved the Society’s application to be registered as a charity in Scotland in early 2010.

As a registered charity, the Society is governed by its Memorandum and Articles of Association. Trustees review these regularly. The most recent revisions were approved by the Charity Commission in December 2016. The document can be viewed at https://www.brit-thoracic.org.uk/about-bts/governance/

Board of Trustees

The Board comprises five honorary officer positions; the Chairs of the Society’s main (Standing) Committees; and up to three others, chosen by the Board for their particular expertise in relevant areas according to the requirements of the Society’s Strategic Plan. A list of all Trustees who served during the year and up to the date this Report was approved appears on page 19.

The Board provides strategic decision-making and direction for those who are responsible for delivering the Society’s operations and activities. The normal term in office for Trustees is three years, as it is for all who serve on BTS Committees and Advisory Groups. All Trustees are made aware of relevant Charity Commission and Companies House Guidance on appointment and are required to undertake induction training provided by the Society’s lawyers and senior staff. Any Trustee may attend refresher training annually if they wish. In accordance with the Society’s constitution the Chair, Honorary Secretary and Honorary Treasurer are selected a year in advance of taking up their posts, to allow some shadowing to take place. An induction programme is provided to the three Honorary Officers in the months before they take up post, and they usually start to attend meetings of the Board of Trustees and Council in the autumn of the year they assume office.

BTS Council

The Society’s Council has a significant role. It comprises 18 elected members plus the President (who chairs meetings of the Council), the Chair of the Board of Trustees and several ex-officio appointments including the Chairs of the BTS Specialty Trainees Advisory Group and the BTS Nurse Advisory Group, the British Paediatric Respiratory Society, British Association of Lung Research and Asthma and Lung UK (formerly the British Lung Foundation). Elections take place annually for 6 new Council members. The constitution requires that one member under the age of 35 should be elected each year.

Council acts as a sounding board for Society policies and a guide for Trustees about general membership opinion. Bi-annual meetings of Council are timed to take place in the mornings before Trustees meet, so that related operational decisions can be made quickly and effectively. Topics covered during the year included the increasing challenges placed on those working in the specialty in the face of the pandemic, continued workforce shortages and the annual Winter Pressures on health systems. Council also considered the Society’s position relating the acquisition of the company Vectura by Philip Morris International in 2021, and amended the BTS Tobacco Position Statement to ensure clarity on the position of companies that found themselves in association with the tobacco industry without intent.

Standing Committees and Specialist Advisory Groups (SAGs)

These important groups enable the Society to organise and deliver core work programmes (the Standing Committees) and communicate quickly and efficiently with expert opinion when required (the Committees and Advisory Groups). Senior staff ensure that the agendas of the Board and Standing Committees are aligned with a focus on how the work of the latter contribute to the Society’s overall strategy, allowing sufficient space for discussion and approval by Trustees of annual work plans of the main Committees. A standard constitution for Committees and SAGs ensures regular and planned turnover of members and consistent methods of operation. The SAG Chairs meet Trustees once a year to discuss strategic and operational matters; and each provides a written report. Each SAG holds an Open Meeting during the Society’s Winter Meeting to report to BTS members and others about their activities and seek feedback.

15

Following suspension of the annual call for new members of Committees and SAGs in 2020, the full round of recruitment to Committees and SAGs took place in 2021 (a total of 55 vacancies) as well as recruitment to the positions of President-Elect, Honorary Secretary (to succeed Dr Lisa Spencer in November 2022) and the chairs of the Quality Improvement Committee and the Science and Research Committee were also advertised in the summer of 2021.

Involving the public

Since 2007 one of the Society’s Trustees has been a lay person. The Society also benefits from patient and carer representation on many of its Guideline and Quality Standards Groups and a system is in place to achieve this. Jason Kalugarama joined the Board as the new BTS Lay Trustee in summer 2021.

Member Engagement and Involvement

The Society’s Strategic Plan mentions that one of the ways by which the Society expects to achieve its objectives is by harnessing the expertise and commitment of its members. The Society had 4,254 members at the end of June 2022 (4,109 in 2021, 3,778 in 2020, 3,349 in 2019 and 3,049 in 2018). 438 members, around 10 % of UK-based members, were engaged in and/or working on BTS projects or in BTS Committees and Advisory and Guideline Groups during the year. They are listed in Appendix A and we wish to record our thanks and gratitude to all of them. We are proud of this level of engagement, which is supported by a robust and democratic framework of access to membership of Committees and Specialist Advisory Groups (SAGs).

Operational Framework

The Trustees are responsible for all strategic and some of the operational decisions taken by the Society. These include allocation of resources in pursuit of the objectives within the Strategic Plan, although the majority of the latter decisions are devolved to the Officers’ Group and most operational decisions are delegated to the Chief Executive and the Senior Management Team.

Standing Financial Instructions exist in relation to decision-making about ordering of goods and services, for authorising expenditure and for authorised signatories on the Society’s accounts. These instructions are reviewed annually by the Chief Executive and Honorary Treasurer, at the time of the annual audit. There are three authorised signatories on the BTS accounts (Chief Executive, Honorary Treasurer and Chair of the Board). There is also clear separation of duties in respect of staff roles and responsibilities for financial activities. The “Items of Reserved Business” statement within the Standing Financial Instructions gives details about what decisions must always be discussed in full by all Trustees, and what can be deferred to the Officers’ Group and/or senior staff. From 2020, the Officers Group has also performed the role of Internal Audit Committee, and receive and consider the annual report from the auditors.

Accounting

The Board considers quarterly management accounts and reports at each of its four meetings during the year, with narrative provided by the Honorary Treasurer and Chief Executive. The narrative focuses on reasons for variation against budget. Operational decisions that might be needed in the meantime are discussed by the five Honorary Officers and Chief Executive, who usually meet monthly (via Teams) and more frequently when required (weekly or fortnightly meetings were held during the peak of the pandemic). Annual budgeting is the responsibility of the Chief Executive and the Society’s accountants, with bi-annual review (at the half -year and end of each financial year). Indicative budgets are prepared for the following two years and the Chief Executive and Honorary Treasurer will review closely at least once a year prior to the year end.

16

Remuneration

The Society established a Remuneration Committee in 2007, which reports to the Board. Its remit is to advise the Trustees about the Society’s pay policy. It meets annually to agree the remuneration of the staff employed by the Society, by considering the recommendations of the Society’s Chief Executive following annual performance development reviews, and considers the remuneration of the Chief Executive. The Committee also reviews the BTS Staff Handbook and annual amendments and updates.

Annual appraisals were conducted in May 2022. The outcome of appraisals inform the recommendations to the Remuneration Committee about pay awards and annual progression of individuals. The Remuneration Committee met in June 2022, and agreed an inflation-linked pay increase of 5% for the 2022/23 which was deemed appropriate in the light of cost of living rises.

Risk Assessment and Management

The Society’s Senior Management Team review the Risk Assessment matrix every quarter, taking actions to mitigate or remove risk as appropriate and where possible, and prepare an update for the Board’s review in June each year. The annual risk review and management plan was undertaken in the final quarter of the year, focussing again on operational and financial recover matters, and the report was approved by the Board in June 2022.

The Senior Management Team monitors the possible impact on income and expenditure of the changes to the way we offer activities such as short courses and the move to and from online conferences for 2021/22. Trustees stand ready to act on advice received and to take steps to maintain the future health of the Society.

Fundraising Practice

The Society does not engage in public fundraising and does not use professional fundraisers or commercial participants. It has not received any complaints relating to fundraising practice.

Related Party Transactions

There were no related party transactions during the year (2021/22: none). Trustees have added into the Standing Instructions for conduct of business the need to treat any further transactions with related parties as an Item of Reserved Business. This means that in future, the Officers’ Group will consider any further situations that might arise, and will make a recommendation to the full Board if they wish to enter into any similar arrangement(s). The Board will be required to give final approval, or otherwise.

Relationship with Biomedical Industries

Since 1999, the Society has had a policy to support its relationship with the biomedical industry, and in all subsequent years has sought related Declarations of Interest from all members who have undertaken work on its behalf. Since June 2013, the Declarations of Interest have been published on the open access area of its website. These come from all who are involved in BTS Committees, Guidelines groups, SAGs and ad-hoc Working Parties. During the year Trustees and Council reviewed and amended this policy, and confirmed the Society’s policy on endorsement which states that, wherever possible, support from a single commercial source for BTS activities should not be sought or accepted. In general, the Society does not endorse any activity – including that which originates from non-commercial organisations - unless it has been involved as a partner from the start. Appendix B gives details of all companies from which the Society received support during the year.

17

STATEMENT OF RESPONSIBILITIES OF TRUSTEES

Members of the Board of Trustees (who are also directors of The British Thoracic Society for the purposes of company law) are responsible for preparing the Board’s report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Board is required to:

Select suitable accounting policies and then apply them consistently

The Board is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). The Board is also responsible for safeguarding the assets of the charitable and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as Board members are aware:

The Board is responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. The total number of such guarantees at 30 June 2022 was 4,254 (2021: 4.109). Each of the Board members are members of the charity but this entitles them only to voting rights. No members of the Board have any beneficial interest in the charity.

The report of the Board has been prepared in accordance with the special provisions applicable to companies subject to the small companies’ regime.

Approved by the Board of Trustees on 4 October 2022 and signed on its behalf by:

Dr Paul Walker

18

Company number 1645201 - Incorporated in the United Kingdom

Charity numbers 285174 – Registered in England and Wales SC041209 – Registered in Scotland

Registered office and operational address

17 Doughty Street London WC1N 2PL

Trustees Trustees, who are also Directors under company law, who served during the year and up to the date of this report were as follows:

----- Start of picture text -----
Trustees Roles
Dr Charlotte Addy Chair, Workforce and Service
Development Committee
Dr Martin Allen MBE Trustee - Getting it Right First Time Lead
Professor Jonathan Bennett Chair of the Board (to December 2021)
Dr Graham Burns President (to December 2021)
Professor James Chalmers Chair, Science & Research Committee
(from December 2021)
Dr Alanna Hare Chair, Education & Training Committee
Dr Simon Hart Chair, Standards of Care Committee
Dr Mark Juniper Chair, Quality Improvement Committee
(from December 2021)
Mr Jason Kalugarama Lay Trustee
Professor Onn Min Kon President-elect (from December 2021)
Mrs Rachael Moses OBE President (from December 2021)
President-elect (to December 2021)
Dr John Park Honorary Treasurer
Dr Jenni Quint Chair, Information Governance
Committee
Dr Elizabeth Sapey Chair, Science & Research Committee
(to December 2021)
Dr Lisa Spencer MBE Honorary Secretary
Professor Michael Steiner Chair, Quality Improvement Committee
(to December 2021)
Dr Paul Walker Chair of the Board
(from December 2021)
Dr Helen Ward Trustee - NHSE Long term Plan
----- End of picture text -----

19

Staff

----- Start of picture text -----
Staff Post
Angela Barnes Membership Manager
Executive Assistant
Deborah Broughton
(Maternity leave from September 2021)
Bernice Bruce-Vanderpuije Co-ordinator, Operations
Giorgio de Faveri Communications Manager
Rajeev Lakhar CRM Manager
Maria Loughenbury Manager, Lung Diseases Registry
Christina Moll Audit Programmes Manager
Head of Strategic Communications,
Rosie O’Carroll
from June 2022
Manager, Guidelines and Clinical
Kirstie Opstad
Standards
Executive Assistant (Maternity cover),
Daniel Passes
from August 2021
Project Manager, Tobacco Dependency
Melanie Perry
Project
Head of Strategy, Education and
Louise Preston
Improvement
Ranjit Nandra IT support
Miguel Souto Head of Clinical Programmes
Joan Thompson Head of Finance & Events
Sally Welham Chief Executive
Kathryn Wilson Head of Operations
----- End of picture text -----

Bankers Co-operative Bank 60 Kingsway London WC2B 6DS Solicitors Taylor Vinters Merlin Place, Merlin Road Cambridge CB4 0DP Investment Tilney Asset Management Limited Managers 6 Chesterfield Gardens London W1J 5BQ

Accountants JS2 Limited One Crown Square, Church Street East Woking Surrey GU21 6HR

Auditor Haysmacintyre LLP 10 Queen Street Place London EC4R 1AG

20

Independent auditor’s report to the members and trustees of The British Thoracic Society

Opinion

We have audited the financial statements of The British Thoracic Society (‘the charitable company’) for the year ended 30 June 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other

21

information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report (which incorporates the strategic report and the directors’ report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charity Accounts (Scotland) Regulations (as amended) require us to report to you if, in our opinion:

Responsibilities of trustees for the financial statements

As explained more fully in the trustees’ responsibilities statement set out on page 20 the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

22

Based on our understanding of the charitable company and the environment in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to the Companies Act 2006, Charities Act 2011, Charity Accounts (Scotland) Regulations (as amended), and Charities and Trustee Investment (Scotland) Act 2005, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as payroll tax and sales tax.

We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to posting inappropriate journal entries to revenue and management bias in accounting estimates. Audit procedures performed by the engagement team included:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of noncompliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

……………………………………………………………… Thomas Wilson (Senior Statutory Auditor) 10 Queen Street Place For and on behalf of Haysmacintyre LLP, Statutory Auditors London EC4R 1AG Date:

23

The British Thoracic Society

Statement of financial activities (incorporating an income and expenditure account)

For the year ended 30 June 2022

----- Start of picture text -----
2022 2021
Unrestricted Restricted Total Unrestricted Restricted Total
Note £ £ £ £ £ £
Income from:
Charitable activities
Membership 2 666,540 666,540 658,019 658,019
Donations 2 56,353 56,353
Standards and Education 2 371,157 40,000 411,157 328,646 40,000 368,646
Research and Innovation 2 1,009,174 1,009,174 1,213,530 1,213,530
Investments 3 51,910 51,910 47,830 47,830
Total income 2,155,134 40,000 2,195,134 2,248,025 40,000 2,288,025
Expenditure on:
Investment Management costs 4 31,708 31,708 38,653 38,653
Charitable activities
Membership 4 120,159 120,159 152,920 152,920
Standards and Education 4 1,067,040 45,920 1,112,960 838,651 29,291 867,942
Research and Innovation 4 572,672 572,672 855,761 855,761
Profile 4 264,608 76,926 341,534 374,448 374,448
Total expenditure 2,056,187 122,846 2,179,033 2,260,433 29,291 2,289,724
Net income / (expenditure) before net gains
on investments 98,947 (82,846) 16,101 (12,408) 10,709 (1,699)
Net gains on investments (24,477) (24,477) 435,562 435,562
Net income / (expenditure) for the year 5 74,470 (82,846) (8,376) 423,154 10,709 433,863
Transfers between funds (116) 116
Net income / (expenditure) and net
movement in funds 74,470 (82,846) (8,376) 423,038 10,825 433,863
Net income / (expenditure) for the year and
net movement in funds 74,470 (82,846) (8,376) 423,038 10,825 433,863
Reconciliation of funds:
Total funds brought forward 17 6,675,786 112,188 6,787,974 6,252,748 101,363 6,354,111
Total funds carried forward 17 6,750,256 29,342 6,779,598 6,675,786 112,188 6,787,974
----- End of picture text -----

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 17 to the financial statements.

24

Company no. 1645201

The British Thoracic Society

Balance sheet

As at 30 June 2022

Note
s
s
e
t
s
:
11
12

a
s
s
e
t
s
:
13

e
s
:
14
17
nrestricted funds
eral funds
h
a
r
i
t
y
f
u
n
d
s
ents
bank and in hand
e assets
s
ed income funds
icted income funds:
ignated funds

d
s
o
f
t
h
e
c
h
a
r
i
t
y
:
e
t
a
s
s
e
t
s
rs: amounts falling due within one year

r
e
n
t
a
s
s
e
t
s		 £
4
2
8
,
6
0
7
1
,
4
6
3
,
5
0
3
1
,
8
9
2
,
1
1
0
(
1
,
0
5
5
,
9
4
8
)
6
,
0
0
8
,
6
4
9
7
4
1
,
6
0
7		 2
0
2
2
£
1
,
5
5
7
,
1
7
7
4
,
3
8
6
,
2
5
9
5
,
9
4
3
,
4
3
6
8
3
6
,
1
6
2
6
,
7
7
9
,
5
9
8
2
9
,
3
4
2
6
,
7
5
0
,
2
5
6
6
,
7
7
9
,
5
9
8		 £
506,298
1,236,261
1,742,559
(1,035,027)
6,105,440
570,346		 2021
£
1,620,279
4,460,163
6,080,442
707,532
6,787,974
112,188
6,675,786
6,787,974

The financial statements have been prepared in accordance with the special provisions applicable to companies subject to th small companies regime. Approved by the Board of Trustees on th October 2022 and signed on its behalf by

Dr

25

The British Thoracic Society

Statement of cash flows

For the year ended 30 June 2022

Note
£
£
18
145,606
51,910
(19,701)
388,218
(166,040)
(172,751)
81,636
227,242
1,236,261
1,463,503
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Net cash provided by / (used in) financing activities
Change in cash and cash equivalents in the year
2022
Cash flows from operating activities
Net cash provided by investing activities
Net cash used in operating activities
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of fixed assets
Proceeds from investments
Movement in cash held by investment managers
Purchase of investments		 £
£
234,433
47,830
814,143
(774,281)
9,922
97,614
332,047
904,214
1,236,261
2021

26

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

1 Accounting policies

a) Statutory Information

The British Thoracic Society is a charitable company limited by guarantee and is incorporated in England and Wales (company registration number 01645201). The registered office address is 17 Doughty Street, London, WC1N 2PL.

b) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Second Edition effective 1 January 2019) (Charities SORP FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (September 2015) and the Companies Act 2006.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy or note.

c) Public benefit entity

The charitable company meets the definition of a public benefit entity under FRS 102.

d) Going concern

The Trustees consider that there are no material uncertainties about the charitable company's ability to continue as a going concern and accordingly have prepared the accounts on a going concern basis.

e) Key judgements and estimation uncertainty

The Trustees do not consider that there are any sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting period.

f) Income

The key income streams are from Journals, Meetings and Membership. Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and that the amount can be measured reliably. Membership income is accounted for in the period to which it relates. Membership reciepts in advance are recorded as deferred income.

Income from government and other grants, whether �capital�grants or �revenue�grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

Income received in advance of the provision of a specified service is deferred until the criteria for income recognition are met.

Investment Income & Interest receivable

Investment income and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

g) Fund accounting

Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund.

Unrestricted funds are donations and other income received or generated for the charitable purposes.

Designated funds are unrestricted funds earmarked by the trustees for particular purposes.

27

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

1 Accounting policies (continued)

h) Expenditure (including grants) and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

Raising funds (investment manager fees)

Expenditure on charitable activities includes the costs ofdelivering services, Meetings and other educational activities undertaken to further the purposes of the charity and their associated support costs

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

i) Allocation of support costs

Expenditure is allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity, comprising the salary and overhead costs of the central function, is apportioned on the following basis which are an estimate, based on staff time, of the amount attributable to each activity.

Standards and Education 37%
Research 6%
Profile 14%
Membership 6%
Support costs 24%
Governance costs 13%
Profile
Membership
Support costs
Governance costs
Research		 24%
13%
6%
14%
6%
Support and governance costs are re allocated to each of the activities on the following basis which is an estimate, based
on staff time, of the amount attributable to each activity
Standards and Education 59%
Research 10%
Profile 22%
Membership 9%

Governance costs, included within total support costs, are the costs associated with the governance arrangements of the charity, namely the costs of constitutional and statutory requirements and include any costs associated with the strategic management of the charity�s activities.

j) Operating leases

Rental charges are charged on a straight line basis over the term of the lease.

1 Accounting policies (continued)

k) Tangible fixed assets

Items of equipment are capitalised where the purchase price exceeds £500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

28

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

Where fixed assets have been revalued, any excess between the revalued amount and the historic cost of the asset will be shown as a revaluation reserve in the balance sheet.

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Fixtures & Fittings 10 years Computer Equipment & Website 3 years CRM Software 10 years Freehold buildings 50 years Land Not Depreciated

l) Listed investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. Any change in fair value will be recognised in the statement of financial activities and any excess of fair value over the historic cost of the investments will be shown as a fair value reserve in the balance sheet. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading �Net gains/(losses) on investments�in the statement of financial activities. The charity does not acquire put options, derivatives or other complex financial instruments.

m) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

n) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

o) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1 Accounting policies (continued)

p) Pensions

BTS established an auto enrolment defined contribution scheme with Legal & General with effect from 1 January 2016 (12 months earlier than required by statute) and makes employer contributions into this scheme. For employees who had their own schemes in place before this date BTS continues to make contributions into their individual schemes. Employer contributions are the same for all employees, on a sliding scale depending on employee contributions as specified in contracts of employment, and those in the auto enrolment scheme increased their contributions during the year in line with statutory minima.

2 Income from charitable activities

29

The British Thoracic Society

Notes to the financial statements

----- Start of picture text -----
2022 2021
For the year ended 30 June 2022
Unrestricted Restricted Total Total
£ £ £ £
Donations
Donations 56,353 56,353
Sub total for Donations 56,353 56,353
Membership
Membership 666,540 666,540 658,019
Sub total for Membership 666,540 666,540 658,019
Standards and Education
Short courses 141,859 141,859 25 5
Summer Meeting 172,269 172,269 103,376
Speciality Certificate Examination 8,179 8,179 24,615
MDRTB project 40,000 40,000 40,000
Tobacco Dependency Programme 40,000 40,000 40,000
Committees 8,850 8,850 35,000
Sub total for Education and Standards 371,157 40,000 411,157 368,646
Research and Innovation
Thorax 565,044 565,044 659,894
Winter Meeting 444,130 444,130 553,637
Sub total for Research and Innovation 1,009,174 1,009,174 1,213,531
Total income from charitable activities 2,103,224 40,000 2,143,224 2,240,196
Prior Year 2021
Unrestricted Restricted Total
£ £ £
Membership
Membership 658,019 658,019
Sub total for Membership 658,019 658,019
Standards and Education
Short courses 125,655 125,655
Summer Meeting 103,376 103,376
Speciality Certificate Examination 24,615 24,615
MDRTB project 40,000 40,000
Tobacco Dependency Programme 40,000 40,000
Clinical statements for community acquired pneumonia 35,000 35,000
Sub total for Education and Standards 328,646 40,000 368,646
Research and Innovation
Thorax 659,894 659,894
Winter Meeting 553,637 553,637
Sub total for Research and Innovation 1,213,531 1,213,531
Total income from charitable activities 2,200,196 40,000 2,240,196
----- End of picture text -----

3 Income from investments

30

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022


Income from listed investments		 Unrestricted
£
51,910
51,910		 £
Restricted		 ~~2022~~
Total
£
51,910
51,910		 ~~2021~~
Total
£
47,830
47,830

31

1tsLnLnrnm￿0 p4 rtmc (¢ Ln f r4 f* mthts)o m¢0 £w m CQ to O O O J J

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

5 Net income / (expenditure) for the year

This is stated after charging / (crediting):

----- Start of picture text -----
|||| |---|---|---| |2022|2021| |£|£| |Depreciation|82,803|77,571| |Operating lease rentals:| |Equipment|1,260|1,440| |Auditors' remuneration (excluding VAT):| |Audit|15,350|14,100|

----- End of picture text -----

Staff costs were as follows:

----- Start of picture text -----
|||| |---|---|---| |2022|2021| |£|£| |Salaries and wages|722,879|699,020| |Social security costs|69,956|75,635| |Employer�s contribution to defined contribution pension schemes|84,450|93,742| |Recruitment|14,580|9,307| |Other forms of employee benefits|346|5,028| |Staff Development & HR|3,720|4,371| |895,931|887,102|

----- End of picture text -----

The following number of employees received employee benefits (excluding employer national insurance and employer pension costs) during the year between:

----- Start of picture text -----
|||| |---|---|---| |2022|2021| |No.|No.| |£60,000|£69,999|1| |£70,000|£79,999|1| |£80,000|£89,999|1| |£90,000|£99,999|1|

----- End of picture text -----

The total employee benefits including employer's national insurance and pension contributions of the key management personnel were £116,927 (2021: £139,303).

No termination payments were made during the year (2021: £nil).

The charity Trustees were not paid or received any other benefits from employment with the charity in the year (2021: £nil). No charity trustee received payment for professional or other services supplied to the charity (2021: £nil).

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs totalling £Nil (2021: £Nil) incurred by £Nil (2021: Nil) members relating to attendance at meetings of the Trustees.

33

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

7 Staff numbers

The average number of employees (head count based on number of staff employed) during the year was as follows:

Membership
Research & Innovation
Profile
Standards & Education
Governance
Support		 2022
No.
0.9
6.0
1.0
2.2
2.1
3.8
16.0		 2021
No.
1.0
4.5
1.4
2.2
1.3
4.2
14.7

8. Grants Awarded

Best Practice Fellowship
BTS Winter Meeting		 2022
Attendees
88
88
88		 2022
£
40,920
40,920
40,920		 2021
Attendees
61
61
61		 2021
£
22,875
22,875
22,875

Best Practice Fellowship

88 grants were made in September 2022 for attendance of the 2022 Winter Meeting.

9 Related party transactions

There were no related party transactions this year, or donations from related parties.

10 Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

34

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

11 Tangible fixed assets

Depreciation
Net book value
Disposals in year
Cost or valuation
At the start of the year
Eliminated on disposal
At the end of the year
At the end of the year
At the start of the year
Charge for the year
At the start of the year
Additions in year
At the end of the year		 Freehold
property
£
1,928,460
1,928,460
416,604
30,769
447,373
1,481,087
1,511,856		 Fixtures and
fittings
£
114,737
114,737
89,787
5,742
95,529
19,208
24,950		 Computer
equipment
£
359,316
19,701
379,017
275,843
46,292
322,135
56,882
83,473		 Total
£
2,402,513
19,701
2,422,214
782,234
82,803
865,037
1,557,177
1,620,279

Land with a value of £390,000 (2021: £390,000) is included within freehold property and not depreciated.

All of the above assets are used for charitable purposes.

12 Listed investments

Fair value at the end of the year
Historic cost at the end of the year
Cash
UK quoted investments
Overseas quoted investments
Disposal proceeds
Fair value at the start of the year
Additions at cost
Net gain on change in fair value
Investments comprise:
Cash held by investment broker pending reinvestment		 2022
£
4,456,520
166,040
(388,218)
(24,477)
4,209,865
176,394
4,386,259
2,635,869
2022
£
463,085
3,746,780
176,394
4,386,259		 2021
£
4,060,820
774,281
(814,143)
435,562
4,456,520
3,643
4,460,163
2,643,766
2021
£
490,217
3,966,302
3,643
4,460,162

35

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

13 Debtors

----- Start of picture text -----
2022 2021
£ £
Trade debtors 17,592 44,405
Other debtors 15,091 27,406
Prepayments 144,208 161,008
Accrued income 251,716 273,479
428,607 506,298
2022 2021
Prepayments includes deposits for future Winter Meetings as follows: £ £
Due in 1 2 years 25,056 25,056
Due in 2 5 years 51,625 57,469
76,681 82,525
Creditors: amounts falling due within one year
2022 2021
£ £
Trade creditors 34,904 22,978
Other creditors 146,398 148,675
Accruals 170,276 176,444
Deferred income (Note 15) 671,683 667,131
Taxes and Social Security 32,687 19,799
1,055,948 1,035,027
----- End of picture text -----

14 Creditors: amounts falling due within one year

15 Deferred income

Deferred income comprises of membership subscriptions received for the period 1 July 2022 to 30 June 2023, to income received for short courses in advance of the course taking place.

Balance at the beginning of the year
Amount released to income in the year
Short Courses
Membership
Delegate Income
Balance at the end of the year		 2022
£
667,131
(667,131)
26,715
638,333
6,635
671,683		 2021
£
588,773
(588,773)
41,994
625,137
667,131

36

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

16 Analysis of net assets between funds 2022

Total restricted funds
Total designated funds
General funds
Analysis of net assets between funds 2021
Tangible fixed assets
Tobacco Dependency Programme
Conference attendance grants
Designated funds:
Unrestricted funds:
Total funds
Total unrestricted funds
Movements in funds 2022
Property Maintenance Fund
Restricted funds:
Investments
Current assets
Current liabilities
Current liabilities
Legacy Fund
Property Fund
Fixed Assets Fund
Investment Fund
Net assets at the end of the year
Current assets
Investments
Tangible fixed assets
Net assets at the end of the year		 At the start
of the year
£
40,000
72,188
112,188
1,511,856
25,000
4,460,161
108,423
6,105,440
570,346
6,675,786
6,787,974		 General
unrestricted
£
1,797,556
(1,055,948)
741,608
General
unrestricted
£
1,605,373
(1,035,027)
570,346
Income
£
40,000
40,000
51,795
56,353
108,148
2,046,986
2,155,134
2,195,134		 Designated
Funds
£
1,557,177
4,386,259
65,213
6,008,649
Designated
Funds
£
1,620,279
4,460,163
24,998
6,105,440
Expenditure
£
(76,926)
(45,920)
(122,846)
(30,769)
(16,140)
(31,708)
(52,034)
(130,651)
(1,925,536)
(2,056,187)
(2,179,033)		 Restricted
£
29,342
29,342
Restricted
£
112,188
112,188
Transfers,
Gains/losses
£
(93,989)
19,701
(74,288)
49,811
(24,477)
(24,477)		 Total funds 2022
£
1,557,177
4,386,259
1,892,111
(1,055,948)
6,779,599
Total funds 2021
£
1,620,279
4,460,163
1,742,559
(1,035,027)
6,787,974
At the end of the
year
£
3,074
26,268
29,342
1,481,087
8,860
4,386,259
76,090
56,353
6,008,649
741,607
6,750,256
6,779,598

17 Movements in funds 2022

37

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

17 Movements in funds 2021

Total restricted funds
Total designated funds
General funds
Fixed Assets Fund
Tobacco Dependency Programme
Conference attendance grants
Restricted funds:
Total unrestricted funds
Unrestricted funds:
Designated funds:
Property Fund
Property Maintenance Fund
Investment Fund
Total funds		 At the start
of the year
£
101,363
101,363
1,542,625
24,999
4,074,385
155,225
5,797,234
455,515
6,252,748
6,354,111		 Income
£
40,000
40,000
47,828
47,828
2,200,196
2,248,024
2,288,024		 Expenditure
£
(29,291)
(29,291)
(30,769)
(15,745)
(38,653)
(46,802)
(131,969)
(2,128,464)
(2,260,433)
(2,289,724)		 Transfers,
Gains/losses
£
116
116
15,746
376,601
392,347
43,099
435,446
435,562		 At the end of the
year
£
40,000
72,188
112,188
1,511,856
25,000
4,460,161
108,423
6,105,440
570,346
6,675,786
6,787,974

38

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

Purposes of restricted funds

Conference attendance grants

Financial support for this scheme came originally from GSK and Vertex in 2017 2018. GSK provided an additional grant of £50,000 in January 2020. The grants are offered in open competition to all respiratory healthcare professionals, and are intended to support the costs of attending respiratory conferences in the UK and the abroad. For 2021, grants were awarded to allow applicants to the scheme to attend the BTS online Winter Meetings at no cost to them. The funders have no input into the criteria for the grants, or the selection of the recipients,

39

The British Thoracic Society

Notes to the financial statements

For the year ended 30 June 2022

Purposes of restricted funds (continued)

Tobacco Dependency Project

The new BTS Tobacco Dependency Project was formally commissioned by NHSEI in March 2021, and the Project Manager, Melanie Perry, joined BTS in June to begin work on a 3 year project which will aim to provide a sustainable framework of resources for improving tobacco dependence treatment by supporting clinicians working in NHS services

Purposes of designated funds

Property Fund

The freehold of 17 Doughty Street was purchased in 2001. The fund balance represents the book value of the property including refurbishment costs. The building was valued in July 2017 £2,800,000.

Property Maintenance Fund

The Society designates funds in order to maintain the building and meet contingencies, and has a five year property maintenance schedule.

Investment Fund

In accordance with the reserves policy outlined in the Trustees Report, this Fund represents the value of the investment portfolio less amounts accrued and committed for refurbishments.

Fixed Asset Fund

The fixed assets fund is equivalent to the net book value of the fixtures and fittings and computer equipment. This fund has been set aside to cover the future depreciation of these fixed assets.

Legacy Fund

BTS received the legacy in 2021/22. Trustees wish to allocate this funding in support of a specific activity to support the new strategic priorities to be published at the end of the year. The Board will confirm the intended use of the legacy funding in early 2023.

18 Reconciliation of net (expenditure) / income to net cash flow from operating activities

Net (expenditure)/income for the reporting period
(as per the statement of financial activities)
Depreciation charges
Loss/(Gains) on investments
Dividends, interest and rent from investments
Decrease in debtors
Increase in creditors
Net cash provided by / (used in) operating activities		 2022
£
(8,376)
82,803
24,477
(51,910)
77,691
20,921
145,606		 2021
£
433,863
77,571
(435,562)
(47,830)
61,582
144,809
234,433

19 Legal Status

The charity is a company limited by quarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

40

A

Huzaifa Adamali Charlotte Addy Ireti Adejumo Sarah Agnew Sanjay Agrawal Rizwan Ahmed Ahsan Akram Paul Albert Raza Alikhan Martin Allen MBE Jamie-Leigh Allen Howard Almond Joseph Aluoch Alan Anderson William Anderson Sarah Anderson Morag Andrew Pearlene Antoine-Pitterson Alison Armstrong Amber Arnold Jamal Arshad Avinash Aujayeb Cristina Avram

B

Mona Bafadhel Peter Bailey Michelle Baker Lucy Baker Christopher Barber Shaney Barratt Sam Bartlett-Pestell Hussain Basheer Simon Baudouin Nick Beare Eihab Bedawi David Bell David Bellamy Rachel Benamore Amy Bendall Jonathan Bennett Joanna Bennett Andrew Bentley Thomas Bewick Anna Bibby Amsalu Binegdie Surinder Birring Kevin Blyth Charlotte Bolton Lee Bolton

Graham Bothamley Stephen Bourke Elinor Bradley Tracey Bradshaw Laura Breach James Brown Lorna Brown Katherine Bunclark Hannah Burke Katie Burke Graham Burns Paul Burns Andrew Bush

C

Matthew Callister Toby Capstick Jane Carre Charlotte Carter Leo Casimo Andrew Chadwick James Chalmers Sarah Chamberlain Mitchell Samantha Chan Michelle Chatwin Nazia Chaudhuri Aneeka Chavda Christabelle Chen Peter Siu Pan Cho Colin Church Amelia Clive Suzi Coles Robin Condliffe David Connell John Corcoran Sonya Craig Hannah Crawford Anjali Crawshaw Andrew Creamer Ian Cropley Heidi Croucher Paul Cullinan

D

Rachel Daly Erika Damato Grainne D'ancona Kavita Dave Alice Davies Jane Davies Michael Davies

41

Rachel Davies Sally Davies Gerry Davies Rebecca D'cruz Duneesha De Fonseka Ruth De Vos Martin Dedicoat Maya Desai Nikesh Devani Anand Devaraj Francis Drobniewski James Duckers Nicholas Duffy

E

Frank Edenborough Anthony Edey Mark Elliott Lynn Elsey Joanna Elverson Odiri Eneje Hazel Evans Matthew Evison Vicky Ewan

F

Matthew Fagg Ahmed Fahim Johanna Feary Timothy Felton Debbie Field Malene Fischer David Fishwick Louise Fleming Sophie Fletcher William Flight Andres Floto Ian Forrest Daryl Freeman Dominika Froehlich-Jeziorek Duncan Fullerton Wendy Funston

G

Erol Gaillard Jessica Gates Johanna Gavlak Emma Gee Peter George Neil Gibson Francis Gilchrist

Mark Gilchrist Ted Goodman Amanda Goodwin Thomas Gorsuch Louis Grandjean Lizzie Grillo Frances Grudzinska Kevin Gruffydd-Jones

H

Guy Hagan Jemma Haines Pranabashis Haldar Rob Hallifax Sarah Haney Fraser Hanks Susan Harden Alanna Hare Katharine Harman Natalie Harper Simon Hart Joanne Heaton Sarah Hennessey Claire Hepworth Louise Hesketh Karen Heslop-Marshall Kirsty Hett Izak Heys Adam Hill Sabrine Hippolyte Ling-Pei Ho Clare Hodkinson Leanne Jo Holmes Stephen Holmes Susan Hope Daniel Horner Luke Howard Freya Howle Jennifer Hoyle Gareth Hughes James Hull Laura Hunter John Hurst John Hutchinson Catherine Hyams

I

Hina Iftikhar Hasnaa Ismail-Koch

42

J

Sunny Jabbal Abigail Jackson David Jackson Phillip Jacobs Shamanthij Jayasooriya Akhilesh Jha Ricky Jones Gavin Jones Andrew Jones Steve Jones Nigel Jones Ricardo Jose Mark Juniper

K

Jason Kalugarama Hanna Kaur Carol Kelly Fasihul Khan Joanne King Ruth Kingshott Merav Kliner Onn Min Kon Neelam Kumar Kartik Kumar Heinke Kunst

L

Lynn Ladbrook Nicholas Lane Ross Langley Hannah Langman Ian Laurenson Hannah Lawrence Iain Lawrie Rod Lawson Moira Leahy Richard Lee Andy Lee Jeong Lee Julian Peter Legg Adam Lewis Keir Lewis Patrick Lillie Eric Lim Wei Shen Lim Rachel Limbrey Marc Lipman Eric Livingston Vikki Lloyd

Lola Loewenthal Tuck-Kay Loke Jayne Longstaff Sharon Loveday Cassandra Lynch

M

Jim Macfarlane Alison Mackenzie Kenneth Macleod Ingrid Madzikanda Hayley Mainman Anirban Maitra Sophia Makki William Man Zaheer Mangera Paul Marsden Matthew Martin Vidan Masani Refiloe Masekela Nick Maskell Alexandros Mathioudakis Hugh Mc Gann David Mccracken Patrick McCrossan Lorcan McGarvey Laura McNaughton Thomas Medveczky Andrew Menzies-Gow Rachel Mercer Ben Messer Fraser Millar Eleanor Mishra Philip Mitchelmore Philip Molyneaux Victoria Molyneaux Andrew Molyneux Olga Moncayo Ramani Moonesinghe Abigail Moore Misha Moore David Moore Alyn Morice Andrew Morley Helen Morris Stephen Morris-Jones Hazel Morrison Kevin Mortimer Rachael Moses OBE Yannick Mouchilli Rahul Mukherjee

43

Mohammed Munavvar Sarah Mungall Anna Murphy Patrick Murphy

Melanie Pritchard Poonam Puthran

Q Jennifer Quint

N

Arjun Nair Manjith Narayanan Neal Navani Michael Newnham Andrew Nicholson Camus Nimmo Farinaz Noorzad

O

Emma O'Dowd James O'Hara Marlies Oostermann Kate Oulton Obianuju Ozoh

P

Evelyn Palmer Rakesh Panchal Padmasayee Papineni Dhruv Parekh John Park Sean Parker Maria Parsonage Padmavathi Parthasarathy Irem Patel Pujan Patel Sheena Patel James Paton Suman Paul Matthew Pavitt Felicity Perrin Melanie Perry Harry Petrushkin Sam Pilsworth Omar Pirzada Marcus Pittman John Plevris Jacqueline Pollington Aravind Ponnuswamy Alison Pooler Jessica Potter Wendy Preston Laura Price Samantha Prigmore Kathryn Prior

R

Ananthakrishnan Raghuram Najib Rahman Sheila Ramjug Kelly Redden-Rowley Angela Reddy Kate Renton William Ricketts Nicola Roberts Helen Roberts Mark Roberts Douglas Robinson Nicola Robinson Ryan Robinson Esther Robinson Helen Rodgers Louise Rose Andrew Rosser Kay Roy Hitasha Rupani Kylie Russo

S

Ravijyot Saggu Martin Samuels Clare Sander Elizabeth Sapey Ramamurthy Sathyamurthy Uli Schwab Stephen Scott Chris Scotton James Seddon Charanjit Sethi Neeraj Shah Anand Shah Charles Sharp Dominick Shaw Bryan Sheinman Stuart Shields Delane Shingadia Murali Shyamsundar Sarah Sibley John Simpson Sally Singh Claire Slinger

44

Derek Sloan Jaclyn Smith Daniel Smith Howard Smith Laura-Jane Smith Lisa Spencer MBE Katherine Spinks Arietta Spinou Koottalai Srinivasan Miles Stanford Andrew Stanton Michael Steiner Margaret Stevenson Iain Stewart Carol Stonham MBE Laura Succony Rajini Sudhir Jay Suntharalingam Ema Swingwood OBE

T

Hui-Leng Tan Alison Tavare Alexandra Teagle Hilary Tedd Shaun Thein Rhys Thomas Mike Thomas Simon Tiberi Muhammad Tufail Alice Turner Daniel Tweedie

W

Steven Walker Paul Walker Naomi Walker Sarah Wallace Gareth Walters Ali Bin Waqar Emily Ward Helen Ward Karen Ward Thomas Ward Richard Ward Anthony Warley Dennis Wat John Watson Tenaya Webb Stephen Webb Nikki Webster Steven Welch Sophie West Douglas West Andrea Whitney Elizabeth Whittaker Melissa Wickremasinghe Tom Wilkinson Mark Wilkinson Andrew Wilson Stephen Wilson Arran Woodhouse Daniel Wootton Dariusz Wozniak

Y

U

Mark Unstead Omar Usmani

Michael Yanney

Z

Sabrina Zulfikar

V

Christopher James Valerio Clare Van Halsema Aashish Vyas

We would also like to thank all those involved in producing BTS guidance related to the COVID-19 pandemic.

45

APPENDIX B: EXTERNAL FUNDING/SUPPORT RECEIVED FOR ANNUAL CONFERENCES AND COURSES List of Exhibitors for the Winter Meeting 2021 held in November 2021

Pharmaceutical Companies

Aquilant/Healthcare 21 AstraZeneca Bioprojet UK Boehringer ngelheim Boston Scientific Chiesi Limited GSK Insmed Irwin Mitchell LLP Janssen Medtronic Napp Olympus Pfizer Sando Sanofi Genzyme Vertex

Charities

Association of Respiratory Nurse Specialists-ARNS Action for Pulmonary Fibrosis European Respiratory Society PCD Support Primary Care Respiratory Society

List of Exhibitors for the Summer Meeting 2022 held in June 2022

Abbott Point of Care APR Medtech AstraZeneca Boston Scientific BOWA MEDICAL UK Broncus Medical Inc /Uptake Medical Chiesi Gilead General Medicine Group Hunan Vathin Medical Instrument Co Ltd Insmed It’s Interventional Ltd Janssen Respiratory Professional Care-Closerstill media Sandoz

Charities

ACPRC Action for Pulmonary Fibrosis

46

British Thoracic Oncology Group INSPIRE Mesothelioma URCP-PRSAS Respiratory ACP Network RCP-PRSAS (Pulmonary Rehabilitation Services Accreditation TOFS European Respiratory Society

List of Exhibitors/Sponsors for BTS Short courses

Erbe Medical Cook UK Richard Wolf Bard Pulmonx UK Olympus Keymed Pentax UK Ltd Rocket Medical Broncus Medical Boston Scientific

47